Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EXXELERATE: Certolizumab Pegol vs Adalimumab in RA
NCT01500278Phase 4Completed
- Sponsor
- UCB
- Start
- Dec 2011
- Primary completion
- Nov 2015
- Modality
- Antibody Fragments, Polymer-based Nanoparticles
- Countries
- 20
01
Overview
Phase 4, randomised, single-blind trial of certolizumab pegol in rheumatoid arthritis (RA) (4 arms), sponsored by UCB. Primary endpoints: American College of Rheumatology 20% Improvement Criteria at 12 weeks and Disease Activity Score 28-Erythrocyte Sedimentation Rate <= 3.2 at 104 weeks. Started Dec 2011; status: completed.
02
Drugs
certolizumab pegol
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT01500278.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01500278.